United States Patent 10,206,813: A Comprehensive Analysis
Overview of the Patent
The United States Patent 10,206,813, titled "Implants with controlled drug delivery features and methods of using same," is a significant innovation in the field of ophthalmology, particularly for the treatment of ocular disorders. This patent, assigned to Glaukos Corporation, outlines advanced drug delivery devices and methods designed to target and control the administration of therapeutic agents within the eye.
Background and Context
Ocular disorders, such as glaucoma, often require precise and controlled drug delivery to manage symptoms and prevent further complications. Traditional methods may not always provide the targeted and sustained release necessary for effective treatment. This patent addresses these challenges by introducing implantable devices with sophisticated drug delivery mechanisms.
Key Components of the Patent
Drug Delivery Devices
The patent describes implantable devices capable of controlled release of one or more drugs. These devices are designed to be inserted into the eye, specifically targeting the anterior chamber or other interior portions, to deliver therapeutic agents directly to the site of the disorder[4].
Controlled Release Mechanisms
The devices feature structures that allow for the controlled elution of drugs. This includes the use of permeable materials, overlapping shell designs, and internal barriers that regulate the release of the therapeutic agents. The degree of overlap and the design of the shell materials can be adjusted to achieve a desired elution profile[4].
Additional Structures for Drug Release
The patent includes descriptions of additional structures within the device, such as proximal barriers and internal plugs, which further control the elution of the drug. These structures ensure that the drug is released at a consistent and predetermined rate[4].
Shunt Features for Intraocular Pressure Management
Some embodiments of the device include shunt features with outflow apertures that facilitate the flow of aqueous humor out of the anterior chamber, helping to manage increased intraocular pressure[4].
Claims of the Patent
Primary Claims
The patent includes claims related to the design and functionality of the implantable devices. These claims cover the composition of the device, including the outer shell, the drug reservoir, and the mechanisms for controlled drug release. Key claims also address the method of implantation and the use of the device for treating ocular disorders[4].
Dependent Claims
Dependent claims elaborate on the specific features and variations of the device. These include details about the material properties, the design of the overlapping shell, and the inclusion of secondary agents with their own elution profiles[4].
Patent Landscape and Related Patents
Prior Art and References
The patent cites numerous prior art references, including earlier patents related to drug delivery systems and ocular implants. These references highlight the evolution of drug delivery technology and the specific innovations introduced by this patent[1][4].
Competing Technologies
Other patents in the field, such as those related to general drug delivery devices, also address controlled release mechanisms but may not be as specifically tailored to ocular disorders. This patent stands out for its focus on targeted and controlled drug delivery within the eye[2].
Economic and Market Impact
Market Need
The demand for effective treatments for ocular disorders is significant, and this patent addresses a critical need in the market. The ability to deliver drugs directly to the eye with controlled release can improve patient outcomes and reduce the need for frequent dosing[4].
Competitive Advantage
Glaukos Corporation, the assignee of this patent, gains a competitive advantage in the ophthalmic device market. The unique features of these implants can differentiate the company's products from those of competitors, potentially leading to increased market share and revenue[4].
Technical and Clinical Significance
Clinical Benefits
The controlled drug delivery mechanism can lead to more consistent and effective treatment of ocular disorders. This can result in better patient outcomes, reduced side effects, and improved quality of life for those suffering from conditions like glaucoma[4].
Technical Innovations
The use of overlapping shell designs, internal barriers, and shunt features represents a significant technical advancement in drug delivery technology. These innovations can be adapted and applied to other areas of medicine beyond ophthalmology[4].
Future Developments and Potential Applications
Expansion of Indications
While this patent is primarily focused on ocular disorders, the technology could be adapted for other conditions requiring targeted and controlled drug delivery. This includes potential applications in neurology, oncology, and other fields[4].
Integration with Other Technologies
Future developments may involve integrating these drug delivery devices with other medical technologies, such as biosensors or smart implants, to enhance their functionality and monitoring capabilities[4].
Key Takeaways
- The United States Patent 10,206,813 introduces advanced implantable devices for controlled drug delivery in the treatment of ocular disorders.
- The devices feature sophisticated mechanisms for controlled release, including overlapping shell designs and internal barriers.
- The patent includes shunt features to manage intraocular pressure.
- The technology has significant clinical and market impact, offering improved patient outcomes and a competitive advantage in the ophthalmic device market.
- Future developments could expand the indications and integrate with other medical technologies.
Frequently Asked Questions (FAQs)
What is the primary purpose of the United States Patent 10,206,813?
The primary purpose is to describe implantable devices with controlled drug delivery features for the treatment of ocular disorders.
How do the devices achieve controlled drug release?
The devices use overlapping shell designs, internal barriers, and other structures to regulate the release of therapeutic agents.
What are the potential clinical benefits of these devices?
The devices can provide more consistent and effective treatment, leading to better patient outcomes and reduced side effects.
Can this technology be applied to other medical fields?
Yes, the technology could be adapted for other conditions requiring targeted and controlled drug delivery, such as neurology and oncology.
How does this patent impact the market for ophthalmic devices?
It provides Glaukos Corporation with a competitive advantage and addresses a significant market need for effective treatments for ocular disorders.
Cited Sources:
- United States Patent and Trademark Office. US10959941.pdf. Retrieved from https://patentimages.storage.googleapis.com/d9/d4/28/1fd1205ce2df27/US10959941.pdf
- Unified Patents. US-20080140024-A1 - Drug Delivery Device. Retrieved from https://portal.unifiedpatents.com/patents/patent/US-20080140024-A1
- United States Patent and Trademark Office. Patent Claims Research Dataset. Retrieved from https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
- Google Patents. US10206813B2 - Implants with controlled drug delivery features and methods of using same. Retrieved from https://patents.google.com/patent/US10206813B2/en
